Semaglutide

In plain English: semaglutide is a man-made version of a hormone your own gut already makes after you eat, called GLP-1 (glucagon-like peptide-1). Natural GLP-1 helps your body handle a meal — it nudges insulin, curbs your appetite, and tells your brain you're satisfied. The problem is that natural GLP-1 breaks down within a couple of minutes. Semaglutide is engineered to do the same job but last about a week, which is why one injection covers seven days.

Chemically, semaglutide is a peptide (a short chain of amino acids) that copies about 94% of human GLP-1, with a few deliberate tweaks. The most important tweak is a fatty-acid chain attached to the molecule that lets it grab onto albumin, a carrier protein in your blood. Riding along on albumin protects semaglutide from being cleared quickly and stretches its half-life to roughly 7 days^[2]. That single design choice — a long half-life from albumin binding — is what made convenient once-weekly dosing possible.

It is sold under several brand names, all from Novo Nordisk, and the brand tells you the dose and the approved use:

• Ozempic — weekly injection, approved for type 2 diabetes (December 2017); a cardiovascular risk-reduction use was later added
• Rybelsus — daily tablet, approved for type 2 diabetes (September 2019); the first oral GLP-1 medication
• Wegovy — weekly 2.4 mg injection, approved for chronic weight management (June 2021); a heart-event-reduction use was added in 2024
• Oral Wegovy — a once-daily semaglutide tablet for obesity, FDA-approved in December 2025, making it the first oral GLP-1 pill cleared specifically for weight loss^[8]

Why the skeptic can trust this one: most compounds discussed in the peptide world have never been tested in a human trial. Semaglutide is the opposite. It has been through large, randomized, double-blind, placebo-controlled studies enrolling tens of thousands of people, and it is fully FDA-approved. When this page cites a number, it comes from human data, and we flag the few places where a claim is weaker than it sounds.

The short version: semaglutide switches on GLP-1 receptors — docking stations found on the pancreas, stomach, and brain — and turning them on produces four effects that together lower blood sugar and reduce how much you eat.

1. Insulin, but only when you need it

Semaglutide stimulates the pancreas to release insulin in a glucose-dependent way — meaning it mostly acts when blood sugar is elevated, such as after a meal, and backs off when blood sugar is normal^[2]. This is a safety feature: because it does not force insulin out at all times, semaglutide on its own carries a low risk of dangerous low blood sugar (hypoglycemia), unlike older drugs such as sulfonylureas or insulin injections.

2. Turning down glucagon

Glucagon is insulin's opposite number — it tells the liver to dump stored sugar into the blood. Semaglutide suppresses inappropriate glucagon release from the pancreas's alpha cells^[2], which keeps the liver from over-producing glucose. The insulin-up, glucagon-down combination is why it is one of the most effective blood-sugar-lowering drugs available.

3. Slowing the stomach

Semaglutide slows gastric emptying — the rate at which food leaves your stomach and moves into the intestine. Food sits longer, you feel full sooner and for longer, and you tend to eat less at the next meal. This same mechanism explains the most common side effect: when the stomach empties slowly, nausea and early fullness are common, especially in the first weeks.

4. Quieting appetite in the brain

This is the effect that drives most of the weight loss. Semaglutide crosses into appetite-control centers in the hypothalamus and brainstem and activates GLP-1 receptors there, reducing hunger and food cravings^[2]. Preclinical work localized the weight-loss effect specifically to GLP-1 receptors in the brain rather than to the gut alone — the drug is essentially changing the signals that tell you how hungry you are.

A bonus: cardiovascular protection

Beyond metabolism, semaglutide reduces cardiovascular risk in ways not fully explained by weight loss or glucose control alone — an effect confirmed in two separate outcome trials (SUSTAIN-6 and SELECT) discussed in the next section. The leading hypothesis is a mix of anti-inflammatory and vascular effects layered on top of the weight and blood-pressure improvements.

Because semaglutide has completed real human trials, we can be specific about what it does, in whom, and how much. Each benefit below follows the same pattern: the plain-English claim, the mechanism, the population studied, the effect size, and the honest limitation.

Weight loss (the headline benefit)

Claim: weekly semaglutide produces large, sustained weight loss in people with obesity. Mechanism: appetite suppression in the brain plus slowed gastric emptying, leading to a lower calorie intake. Population & effect size: in STEP 1 — the landmark trial of 1,961 adults with overweight or obesity but without diabetes — semaglutide 2.4 mg weekly produced a mean body-weight change of −14.9% versus −2.4% on placebo over 68 weeks (a 12.4-point difference; roughly 15.3 kg lost versus 2.6 kg)^[1]. Limitation: results in people who also have type 2 diabetes are more modest (closer to 9–10%), and individual response varies widely — some lose more than 20%, others much less.

A pill that works nearly as well as the shot

Claim: high-dose oral semaglutide can approach the weight loss of the injection. Mechanism: identical GLP-1 receptor agonism, delivered as a daily tablet. Population & effect size: in the OASIS 1 trial of adults with overweight or obesity without diabetes (N=667), oral semaglutide 50 mg once daily gave an estimated treatment difference of −12.7 percentage points versus placebo over 68 weeks, and 85% of participants lost at least 5% of body weight versus 26% on placebo^[5]. Limitation: the tablet has very low absorption and must be taken on an empty stomach with strict timing (covered in the dosage section), and cross-trial comparisons to the injection are not the same as a head-to-head study.

Cardiovascular risk reduction

Claim: semaglutide lowers the risk of heart attack, stroke, and cardiovascular death in high-risk patients. Mechanism: combined vascular, anti-inflammatory, weight, blood-pressure, and glucose effects. Population & effect size: the SELECT trial randomized 17,604 adults who had established cardiovascular disease and overweight or obesity but no diabetes. Over about 40 months, the primary endpoint of major adverse cardiovascular events fell to 6.5% on semaglutide versus 8.0% on placebo — a 20% relative reduction (hazard ratio 0.80, 95% CI 0.72–0.90, P<0.001)^[4]. This was the first time a weight-loss medication was shown to prevent heart events in people without diabetes. The earlier SUSTAIN-6 trial had already shown a similar benefit in 3,297 people with type 2 diabetes — a 26% reduction in the primary cardiovascular endpoint (6.6% vs 8.9%, HR 0.74)^[3]. Limitation: these benefits were shown in high-risk populations; they should not be assumed for a healthy person taking semaglutide purely for cosmetic weight loss.

Blood-sugar control in type 2 diabetes

Claim: semaglutide is among the strongest non-insulin glucose-lowering drugs. Mechanism: glucose-dependent insulin release plus glucagon suppression. Effect size: in the diabetes trial programs it lowered HbA1c (a three-month average of blood sugar) by roughly 1.5 percentage points, with low hypoglycemia risk because the insulin effect is glucose-dependent. Limitation: it does not replace insulin in people whose pancreas produces very little of their own.

Liver disease (promising but partial)

Claim: semaglutide can improve non-alcoholic steatohepatitis (NASH, now often called MASH — fatty liver with inflammation). Mechanism: weight loss and improved metabolic signaling reduce liver fat and inflammation. Population & effect size: in a Phase 2 trial of 320 patients with biopsy-confirmed NASH and fibrosis stages F1–F3, NASH resolution without worsening of fibrosis occurred in 59% on semaglutide 0.4 mg/day versus 17% on placebo (P<0.001)^[7]. Limitation — read this carefully: the trial did not show a significant improvement in fibrosis (scarring) stage, which is the outcome most tied to long-term liver damage. So the honest summary is that semaglutide calmed inflammation but did not clearly reverse scarring in this study — a meaningful but incomplete benefit, and one where it is not yet FDA-approved for liver disease.

Does the weight stay off?

This is the most important limitation of the whole class. In the STEP 4 trial, participants first reached the 2.4 mg dose over a 20-week run-in, then were split into continuing the drug or switching to placebo. Those who continued lost a further 7.9% of body weight from week 20 to 68, while those switched to placebo regained 6.9% — a 14.8-point gap^[6]. The takeaway is blunt: semaglutide manages weight while you take it, and weight tends to return after you stop. It is a long-term treatment, not a short course.

The core idea: semaglutide is started low and increased slowly. This gradual "titration" is not arbitrary — it is specifically designed to reduce the nausea and other gut side effects that come from ramping up too fast. The doses below are the FDA-labeled prescription regimens, listed for education; semaglutide is a prescription medication and should be dosed by a clinician.

Prescription protocols by product

Brand	Indication	Starting dose	Target / max	Route
Ozempic	Type 2 diabetes	0.25 mg/week × 4 weeks	0.5–2.0 mg/week	SC injection
Wegovy	Weight management	0.25 mg/week × 4 weeks	2.4 mg/week; up to 7.2 mg since March 2026	SC injection
Rybelsus	Type 2 diabetes	3 mg/day × 30 days	7–14 mg/day	Oral tablet

The Wegovy 16-week escalation schedule

For weight management, the injection climbs through five steps before reaching the maintenance dose^[1]:

• Weeks 1–4: 0.25 mg once weekly
• Weeks 5–8: 0.5 mg once weekly
• Weeks 9–12: 1.0 mg once weekly
• Weeks 13–16: 1.7 mg once weekly
• Week 17 onward: 2.4 mg once weekly (maintenance)
• Optional, since March 2026: after at least 4 weeks at 2.4 mg, the dose may go to 7.2 mg once weekly if further weight reduction is clinically indicated. This applies to weight reduction in adults only — cardiovascular risk reduction, pediatric use and the fatty-liver (MASH) indication all stay at 2.4 mg or lower.

If a dose bump is not tolerated, clinicians commonly hold at the current step longer before advancing. Ozempic for diabetes escalates more gently, typically toward a 0.5–2.0 mg maintenance dose.

How to take each form

• Injectable (Ozempic / Wegovy): supplied in pre-filled pens — no mixing required. Inject subcutaneously (into the fat just under the skin) in the abdomen, thigh, or upper arm, the same day each week, at any time of day, with or without food. Rotate injection sites.
• Oral (Rybelsus / oral Wegovy): take first thing in the morning on an empty stomach with no more than 4 oz (about half a cup) of plain water, then wait at least 30 minutes before any food, drink, or other medication. This is not a suggestion — the tablet's absorption is very low and food or extra water wipes it out.

Reconstitution math (for lyophilized/compounded powder)

Brand pens come ready to use, but compounded semaglutide is often supplied as a lyophilized (freeze-dried) powder that must be mixed with bacteriostatic water. Here the math matters, because a dosing error with a GLP-1 drug means real side effects. Worked example: say you have a 5 mg vial and add 2 mL of bacteriostatic water.

• Concentration = 5 mg ÷ 2 mL = 2.5 mg/mL (i.e., 2,500 mcg/mL)
• For a 0.25 mg (250 mcg) starting dose: 0.25 mg ÷ 2.5 mg/mL = 0.10 mL, which is 10 units on a U-100 insulin syringe
• For a 0.5 mg dose: 0.5 ÷ 2.5 = 0.20 mL = 20 units

A common error is confusing milligrams with syringe "units" — always convert to the volume your syringe measures. Compounded products vary in concentration and quality, so this section is illustrative, not a recommendation to self-compound. See the oral vs. injectable section for the compounded-versus-brand debate and the current legal picture.

Timing, duration, and missed doses

• Duration: there is no "cycle." Semaglutide is intended for long-term use; STEP 4 showed weight returns after stopping^[6].
• Missed injection: if it is within 5 days of the scheduled day, take it as soon as you remember; if more than 5 days have passed, skip it and resume the normal schedule.
• Missed tablet: skip the missed dose and take the next one the following morning — do not double up.

Storage

• Unopened pens: refrigerate at 2–8°C; do not freeze.
• In-use pens: room temperature (up to 30°C) or refrigerated for up to 56 days.
• Tablets: room temperature in the original blister pack.

Semaglutide comes in two very different delivery formats, and choosing between them is one of the most common questions people have. The injectables — Ozempic (diabetes) and Wegovy (weight management) — have been on the market since 2017 and 2021. The oral tablets are newer: Rybelsus (diabetes) arrived in 2019 as the first oral GLP-1, and in December 2025 the FDA approved the once-daily Wegovy pill (oral semaglutide 25 mg) for weight management — the first oral GLP-1 cleared specifically for obesity^[8]. Same molecule, same GLP-1 receptor agonism; the difference is entirely in how the drug gets into your body.

Why a pill was hard to make: SNAC and bioavailability

Peptides are normally destroyed by stomach acid and digestive enzymes, which is why GLP-1 drugs were injection-only for years. Oral semaglutide gets around this by being co-formulated with SNAC (sodium N-[8-(2-hydroxybenzoyl)amino] caprylate), an absorption enhancer. SNAC locally raises the pH right around the tablet to shield semaglutide from acid, and it promotes transcellular absorption — the peptide passes directly through the cells of the stomach lining in a small zone next to the dissolving tablet^[9]. Even so, oral bioavailability is only about 0.4–1%, versus roughly 89% for the subcutaneous injection. That gap is why the oral doses are so much larger (3–14 mg for Rybelsus, 25 mg for the Wegovy pill) than the injectable doses (0.25–2.4 mg), and why the tablet must be taken on an empty stomach with no more than 4 oz of plain water and a 30-minute wait before anything else — food, coffee, or extra water sharply cut absorption.

How the two forms compare

Factor	Oral semaglutide	Injectable semaglutide
Brands	Rybelsus (diabetes), Wegovy pill (obesity)	Ozempic (diabetes), Wegovy (obesity)
Dosing frequency	Once daily	Once weekly
Dose range	3–14 mg (Rybelsus); 25 mg (Wegovy pill)	0.25–2.0 mg (Ozempic); 2.4 mg (Wegovy)
Bioavailability	~0.4–1%	~89%
Trial weight loss	~15.1% at 50 mg (OASIS 1, 68 wks)	~14.9% at 2.4 mg (STEP 1, 68 wks)
Administration	Empty stomach, plain water, 30-min fast after	Any time, with or without food
Storage	Room temperature	Refrigerated; room temp up to 56 days in use
Needle required	No	Yes (pre-filled pen)
Compounded option	No	Yes (injectable only)

Do they work equally well?

For weight loss, remarkably yes. In the OASIS 1 trial, oral semaglutide 50 mg once daily produced about 15.1% mean body-weight loss over 68 weeks^[5] — statistically in the same range as the 14.9% seen with the 2.4 mg injection in STEP 1^[1]. The FDA-approved Wegovy pill uses the 25 mg dose, which in the OASIS 4 trial delivered weight loss comparable to the injection^[8]. For type 2 diabetes, the oral form was established by the PIONEER program: PIONEER 1 showed oral semaglutide monotherapy significantly lowered HbA1c versus placebo^[10]. One caveat: OASIS-versus-STEP is a cross-trial comparison, not a head-to-head study, so treat "equivalent" as "very close" rather than proven identical.

Side effects: same profile, different rhythm

Both forms share the GLP-1 class's gastrointestinal side effects, and discontinuation for GI reasons is similar (about 7% in both programs). The main practical difference is timing: the weekly injection tends to produce a peak of nausea in the first days after each dose, while the daily tablet spreads a lower-grade, more consistent nausea across the week. Daily dosing also makes it a little easier to pause or step back if side effects flare. Only the injectable carries injection-site reactions (mild redness or swelling in 1–2%). The serious warnings — pancreatitis, gallbladder events, the rodent-based thyroid C-cell boxed warning, and possible worsening of pre-existing diabetic retinopathy — apply identically to both, because the active drug is the same.

Cost and access

At list price the brands are expensive: roughly $1,350/month for the Wegovy injection and about $935/month for Ozempic and Rybelsus, with the Wegovy pill in a similar four-figure range. Manufacturer savings cards can cut out-of-pocket cost to as little as $0–25/month for some commercially insured patients, but those do not apply to Medicare or Medicaid. Diabetes indications (Ozempic, Rybelsus) are more widely covered than weight-management ones. The cheapest route many people find — compounded semaglutide at roughly $150–500/month — exists only as an injectable, and comes with real quality caveats.

Compounded vs. FDA-approved

During the 2022–2024 shortage, compounding pharmacies were permitted to prepare semaglutide copies. After the FDA declared the shortage resolved in late 2024, that pathway was sharply restricted and the market has been in legal flux since. Compounded semaglutide is not FDA-approved, is not required to prove bioequivalence, and FDA testing has found both sub-potent and super-potent batches; the agency has also flagged unapproved salt forms (semaglutide sodium and acetate), dosing-error injuries, and fraudulently labeled products^[11]. If you are weighing a non-brand injectable, insist on a state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility and a batch-specific Certificate of Analysis. Where insurance or a savings program makes the approved product feasible, it is the higher-confidence choice.

Which form should you choose?

The oral pill tends to fit if you have needle anxiety, travel often (no refrigeration, no sharps), prefer a daily routine, or want the easier day-to-day dose adjustments that daily dosing allows. The injection tends to fit if you prefer once-weekly simplicity, take other morning medications or coffee that clash with the 30-minute empty-stomach window, want the reliability of ~89% absorption, have a GI condition that makes oral absorption unpredictable, or are using a lower-cost compounded product (injectable only). Switching between forms is done in practice and was studied directly — OASIS 3 showed people moving from the injection to the oral form kept their weight loss — but dose equivalence is only approximate (oral 50 mg/day roughly tracks the 2.4 mg weekly injection), so make any switch with a prescriber. Ultimately the best form is the one you will take consistently.

Bottom line: the vast majority of side effects are digestive, tend to be mild to moderate, and are worst while the dose is being increased. In the STEP weight-management program, about 7% of participants stopped treatment because of gastrointestinal side effects — meaning roughly 93% tolerated it well enough to continue^[1]. The serious risks are rare but real, and a few groups should not take it at all.

Common side effects (gastrointestinal)

These come directly from slowed gastric emptying and are most intense in the first weeks at each new dose:

• Nausea (20–44%): the most common effect; usually eases within 2–4 weeks at a given dose
• Diarrhea (8–30%): generally mild and self-limiting
• Vomiting (5–24%): more likely during dose increases
• Constipation (5–24%): the flip side of slowed digestion
• Abdominal pain (5–20%): usually mild; persistent or severe pain warrants a call to your clinician

Managing them: smaller meals, going easy on high-fat and greasy foods, staying hydrated, and — most importantly — not rushing the dose escalation. Most people see substantial improvement after the first 4–8 weeks at a stable dose.

Less common effects

• Headache and fatigue: common early, usually transient
• Injection-site reactions (1–2%): mild redness or swelling that resolves
• Hair thinning: reported in post-marketing use; most likely a consequence of rapid weight loss and reduced calorie intake (a temporary shedding called telogen effluvium) rather than a direct drug effect. Adequate protein may help.
• Muscle (lean mass) loss: as with any large, fast weight loss, a meaningful share of the weight lost can be muscle. Resistance training and higher protein intake (roughly 1.2–1.6 g/kg/day) help preserve it.

Serious but rare risks

• Pancreatitis: acute inflammation of the pancreas has been reported. Severe, persistent abdominal pain that radiates to the back is a red flag — stop the drug and seek care.
• Gallbladder problems: gallstones and cholecystitis occur more often, largely because rapid weight loss itself promotes gallstone formation.
• Thyroid C-cell tumors (boxed warning): GLP-1 drugs caused thyroid C-cell tumors in rodents. This has not been confirmed in humans at clinical doses, but out of caution semaglutide carries the FDA's strongest warning and is contraindicated in people with a personal or family history of medullary thyroid carcinoma (MTC) or MEN2.
• Diabetic retinopathy: in people with pre-existing eye disease, rapid blood-sugar improvement can transiently worsen it; eye monitoring is advised for that group.

Who should not take it, and drug interactions

Contraindicated / avoid in: personal or family history of MTC or MEN2; known hypersensitivity to semaglutide; pregnancy and breastfeeding (the label advises stopping at least 2 months before a planned pregnancy); and caution with a history of pancreatitis.

Interactions to know:

• Insulin or sulfonylureas: combining raises hypoglycemia risk; those doses often need to be reduced.
• Other oral medications: slowed stomach emptying can change how quickly other pills are absorbed — take time-sensitive drugs (e.g., certain thyroid or contraceptive medications) as directed and flag the combination to your prescriber.

For broader context, see Are Peptides Safe? and compare with tirzepatide if semaglutide's side effects are limiting.

The honest picture: semaglutide is unusual in this space because a fully FDA-approved, quality-controlled version exists. That should be the default. The complications come from cost and from the large "compounded" market that grew during the 2022–2024 shortage.

Legal status

Semaglutide is a prescription drug, not a research chemical and not a controlled substance. The brand products — Ozempic, Wegovy, Rybelsus, and oral Wegovy — are FDA-approved and dispensed through pharmacies with a prescription^[8]. This is a genuinely different legal footing from most peptides, which are sold "for research use only."

Compounded semaglutide: what changed

During the FDA-declared shortage, compounding pharmacies were permitted to prepare semaglutide copies. In late 2024 the FDA declared the shortage resolved, which sharply restricted that pathway; the market has been in legal flux since, with lawsuits and enforcement actions ongoing. Compounded products are not FDA-approved, are not required to prove bioequivalence to the brand, and have variable oversight — FDA testing has found both sub-potent and super-potent compounded batches. The full breakdown lives in the oral vs. injectable section below.

If you are evaluating a non-brand source

• Verify the facility: a state-licensed 503A pharmacy with a valid prescription, or an FDA-registered 503B outsourcing facility inspected for sterile manufacturing.
• Ask for a batch-specific Certificate of Analysis (COA): it should show HPLC purity and mass-spectrometry identity for your lot, not a generic sample.
• Sterility matters for injectables: a contaminated injection is a real infection risk.
• Watch for red flags: "for human use" marketing on an unapproved product, prices far below market, and no COA.

Our recommendation: where insurance coverage or a manufacturer savings program makes it feasible, the FDA-approved product is the higher-confidence choice. Discuss any compounded option with a prescriber.

Semaglutide is one of several GLP-1-based therapies, each with a distinct receptor profile and evidence base. For the full landscape, see the complete GLP-1 guide.

• Tirzepatide (Mounjaro/Zepbound): a dual GLP-1/GIP agonist that produced up to 22.5% weight loss in the SURMOUNT-1 trial and beat injectable semaglutide in a head-to-head study — often the next step if semaglutide underdelivers. See tirzepatide vs semaglutide.
• Retatrutide: a triple GLP-1/GIP/glucagon agonist in Phase 3 trials showing up to ~24% weight loss, with the glucagon arm adding energy expenditure and strong liver-fat reduction.
• Liraglutide (Victoza/Saxenda): the first-generation, daily GLP-1 agonist; less weight loss (~8%) than semaglutide but a longer track record.
• Cagrilintide (CagriSema): an amylin analog studied combined with semaglutide, targeting two appetite pathways at once.
• Survodutide: a dual GLP-1/glucagon agonist with notable MASH (fatty-liver) improvement data.
• Mazdutide: another dual GLP-1/glucagon agonist in Phase 3, studied primarily in China.

For a whole-program approach, see the weight loss stack and the weight loss peptides guide.